Clinical trials: Cancer Progression
Heart Failure, Diastolic
HbA1c as an Early Serologic Marker for the Hemodynamic Progression of Stage A Heart Failure
In a retrospective community based cohort study from Pueblo County Colorado which has a higher population proportion of metabolic syndrome and diabetes mellitus, we hope to clarify and quantify an association of the AGE HBa1c…
- Trial name
- NCT04450576
- Testing
- Glycosylated hemoglobin
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Parkview Medical Center
Age-related Macular Degeneration
Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)
The VITamin D and OmegA-3 Trial (VITAL; NCT 01169259) is a randomized clinical trial in 25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor fish…
- Trial name
- NCT01782352
- Testing
- Omega-3 fatty acids (fish oil), Vitamin D3
- Where
- United States
- Volunteers
- 25,871 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Disorder of the Lower Urinary Tract
Changes of microRNA Expression in Obstructive and Neurogenic Bladder Dysfunction
Patients with obstructive or neurogenic lower urinary tract disease will be invited to participate. Upon agreement they will undergo an assessment of bladder function (questionnaires) and bladder biopsies at 2 time-points.
- Trial name
- MoVe (NCT02410876)
- Testing
- Bladder biopsy, Urodynamic study
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Neuroendocrine Tumors, Carcinoma, Neuroendocrine
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
Background: Neuroendocrine neoplasm (NENs)are rare cancers arising from the neuroendocrine cells and can affect almost any part of the body.
- Trial name
- NCT05237934
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- National Cancer Institute (NCI)
Decompensated Cirrhosis
Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis
It is still not clear whether rifaximin can prevent the progression of liver cirrhosis, reduce the overall complications and improve the survival in patients with decompensated cirrhosis.
- Trial name
- RPPCLC (NCT05863364)
- Testing
- Low-dose of Rifaximin, Conventional dose of Rifaximin
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Xin Zeng
Pulmonary Fibrosis
Exhaled Breath Analysis Using eNose Technology as a Biomarker for Diagnosis and Disease Progression in Fibrotic ILD
The ILDnose study a multinational, multicenter, prospective, longitudinal study in outpatients with pulmonary fibrosis. The aim is to assess the accuracy of eNose technology as diagnostic tool for diagnosis and differentiation…
- Trial name
- ILDnose (NCT04680832)
- Testing
- Electronic nose
- Where
- 5 sites in Australia, France and 3 more
- Volunteers
- 600 people
- Sponsor
- Erasmus Medical Center
Colorectal Cancer
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00588900
- Testing
- cediranib maleate, irinotecan hydrochloride
- Where
- 31 sites in United States
- Volunteers
- 5 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Castration-Resistant Prostate Cancer, mCRPC
REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants
This study will test an experimental Regeneron drug called REGN21353 ("study drug") to see if it can help treat previously treated prostate cancer that has spread (also called metastatic castration-resistant prostate cancer or…
- Trial name
- NCT07850921
- Testing
- REGN21353, Nezastomig, Sarilumab Prophylaxis (Contingency)
- Volunteers
- 192 people
- Sponsor
- Regeneron Pharmaceuticals
Myopia, Progressive
DIMS-myopia Progression ADN Axial Length Growth
To confirm the efficacy of DIMS lenses in controlling myopia progression, we planned a prospective randomized controlled clinical study.
- Trial name
- NCT05300321
- Testing
- frame lens
- Where
- China
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Tianjin Eye Hospital
Multiple Myeloma
Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma
In a small case series, the investigators identified five patients who had an initial response to standard daratumumab (weekly for 2 cycles, every other week for 4 cycles, then monthly thereafter) either as mono- or combination…
- Trial name
- NCT04150692
- Testing
- Dara-SC, Blood for research assessments, Bone marrow for research assessments
- Sponsor
- Washington University School of Medicine
Multiple Myeloma
Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD
The purpose of this study is to test the effectiveness and safety of adding cyclophosphamide or lenalidomide to the VD combination in the treatment of patients with multiple myeloma that have achieved a stable response after 4…
- Trial name
- SEQUENTIAL (NCT00908232)
- Testing
- Cyclophosphamide, Bortezomib, Dexamethasone
- Where
- 42 sites in France, Germany and 8 more
- Volunteers
- 163 people
- Sponsor
- Janssen-Cilag International NV
Glioblastoma Multiforme, Gliosarcoma
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
Background: Growth of new blood vessels (angiogenesis) provides many tumors, including brain tumors, with needed nutrients and oxygen for cancer cells to survive.
- Conditions
- Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00995007
- Testing
- ZD6474 (Vandetanib), Carboplatin
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- National Cancer Institute (NCI)
Sepsis, Infection
Evaluation of the Heparin Binding Protein Levels in Sepsis
Present criteria used to define sepsis are non-specific, making it difficult to both distinguish sepsis from other diseases and to predict which patients are likely to become more severely ill.
- Conditions
- Sepsis, Infection, Septic Shock
- Trial name
- HBP (NCT02533011)
- Testing
- HBP lab test
- Where
- United States
- Volunteers
- 1,055 people
- Sponsor
- Christiana Care Health Services
Multiple Sclerosis
Evaluation of Clinical, Morphologic and Biochemical Markers in Multiple Sclerosis
By combining clinical, morphological and biochemical markers a better understanding of the formation and progression of multiple sclerosis (MS) should be obtained
- Trial name
- NCT04892134
- Testing
- blood sample
- Where
- Austria
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
CKD
Neutrophil-to-Lymphocyte and Platelet-to-lymphocyte Ratios as a Predictor Factors for Chronic Kidney Disease Progression
In this study, we aim to investigate whether NLR and PLR levels are associated with decline of kidney function in patients with CKD.
- Trial name
- NCT06670599
- Volunteers
- 200 people
- Sponsor
- Assiut University
Non-Small Cell Lung Cancer
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung cancer (NSCLC).
- Trial name
- EVOKE-01 (NCT05089734)
- Testing
- Sacituzumab Govitecan-hziy (SG), Docetaxel
- Where
- 227 sites in United States, Australia and 18 more
- Volunteers
- 603 people
- Sponsor
- Gilead Sciences
Diffuse Large B Cell Lymphoma
Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL
The main objective of this study is to observe the overall survival of Rituximab Biosimilar HLX01 and MabThera in Combination With CHOP, in previously untreated subjects with CD20+ DLBCL.
- Trial name
- NCT04491721
- Where
- China
- Volunteers
- 407 people
- Sponsor
- Chinese Academy of Medical Sciences
Chondrosarcoma
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas
The mainstay of chondrosarcoma treatment is a wide surgical resection. Unfortunately, this is a rare occurrence, and patients with incomplete resection have very poor therapeutic options.
- Trial name
- CHONRAD (NCT02008019)
- Testing
- Everolimus 2.5 mg/day, Everolimus 10 mg/day
- Where
- 12 sites in France
- Volunteers
- 57 people
- Sponsor
- Centre Leon Berard
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy
This randomized clinical trial is studying the side effects of oregovomab and to see how well it works with or without cyclophosphamide in treating patients with stage III or stage IV ovarian epithelial cancer, fallopian tube…
- Conditions
- Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage III Ovarian Cancer
- Trial name
- NCT00551265
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Oregovomab
- Where
- United States
- Sponsor
- Gynecologic Oncology Group
Abdominal Aortic Aneurysm
Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms
The purpose of this study is to determine if telmisartan is effective in slowing the progression of abdominal aortic aneurysms and reducing circulating concentrations of Abdominal Aortic Aneurysms (AAA) biomarkers.
- Trial name
- TEDY (NCT01683084)
- Testing
- Telmisartan
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Palo Alto Veterans Institute for Research